Minimed GroupMMED +0.14%15 EBITDA Margin % is -6.84% as of Jan. 2026. GuruFocus rates MMED with a GF Score™ of 15/100. The stock has 1 warning sign investors should review. Among 816 Medical Devices & Instruments companies, Minimed Group ranks worse than 64.09% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Minimed Group's EBITDA for the
three
months ended in Jan. 2026 was $-54 Mil. Minimed Group's Revenue for the
three
months ended in Jan. 2026 was $790 Mil. Therefore, Minimed Group's EBITDA margin for the quarter that ended in Jan. 2026 was -6.84%.
Minimed Group (NAS:MMED) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Minimed Group EBITDA Margin % Related Terms
Minimed Group EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Minimed Group's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Minimed Group EBITDA Margin % Chart
Minimed Group Annual Data
Trend
Apr23
Apr24
Apr25
EBITDA Margin %
2.05
2.43
3.94
Minimed Group Quarterly Data
Apr24
Jan25
Apr25
Oct25
Jan26
EBITDA Margin %
0.00
8.59
0.00
0.00
-6.84
MMED vs ICUI, WRBY, MMSI: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Minimed Group's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Minimed Group EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Minimed Group's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Minimed Group's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Minimed Group (MMED) has a EBITDA Margin % of -6.84% as of Jan. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Minimed Group and its competitors. According to the industry distribution chart, Minimed Group ranks #523 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 64.1%.
Is Minimed Group's EBITDA Margin % too high?
Minimed Group's current EBITDA Margin % is -6.84%. Based on the distribution chart, Minimed Group ranks #523 out of 816 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Minimed Group has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Minimed Group's EBITDA Margin % compare to ICUI and WRBY?
According to the Medical Devices & Instruments industry distribution chart, Minimed Group ranks #523 out of 816 companies for EBITDA Margin %. This places Minimed Group in the lower half of its industry. The industry median EBITDA Margin % is 7.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Minimed Group and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Minimed Group's current EBITDA Margin % is -6.84%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minimed Group stock overvalued right now?
Minimed Group (MMED) has a current EBITDA Margin % of -6.84%. The current EBITDA Margin % is -6.84%. Minimed Group's overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Minimed Group (MMED), the current EBITDA Margin % is -6.84% as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Minimed Group Inc is a medical technology firm that develops, manufactures, and markets products and solutions for diabetes management. It offers automated insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens as its main products. The company sells these through direct-to-consumer channels and healthcare providers of various countries. The company's revenues are principally derived from the sale of reusable and single-use products which together comprise AID systems and smart multiple daily injection (MDI) systems for diabetes management to individuals, distributors, healthcare providers, and other institutions globally.
15GF Score
Get the complete analysis for MMED
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MMED has been successfully added to your 